MIRA INFORM REPORT

 

 

Report No. :

320235

Report Date :

06.05.2015

 

IDENTIFICATION DETAILS

 

Name :

POKUPHARMA GHANA LTD

 

 

Registered Office :

Near Asafo Ahmadiyya Mosque, P. o. Box 3009/64220 Kumasi

 

 

Country :

Ghana

 

 

Date of Incorporation :

05.03.1998

 

 

Com. Reg. No.:

CA 32859

 

 

Legal Form :

Limited Corporation 

 

 

Line of Business :

Suppliers of pharmaceutical products and medicinal drugs

 

 

No of Employees :

25

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – December 31, 2014

 

Country Name

Previous Rating

(30.09.2014)

Current Rating

(31.12.2014)

Ghana

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low Risk

 

A2

Moderate Low Risk

 

B1

Moderate Risk

B2

Moderate High Risk

 

C1

High Risk

C2

Very High Risk

D

 

 

GHANA ECONOMIC OVERVIEW

 

Ghana's economy was strengthened by a quarter century of relatively sound management, a competitive business environment, and sustained reductions in poverty levels, but in recent years has suffered the consequences of loose fiscal policy, high budget and current account deficits, and a depreciating currency. Ghana has a market-based economy with relatively few policy barriers to trade and investment in comparison with other countries in the region. Ghana is well-endowed with natural resources. Agriculture accounts for nearly one-quarter of GDP and employs more than half of the workforce, mainly small landholders. The services sector accounts for about half of GDP. Gold and cocoa exports, and individual remittances, are major sources of foreign exchange. Expansion of Ghana’s oil industry is expected to boost economic growth. Production at Jubilee, Ghana's offshore oil field, began in mid-December 2010 and is expected to double Ghana’s oil output between 2014 and 2017. The administration faces dissent from a population that is unhappy with the high cost of living and perceives that the gains from oil are going to the politically corrupt. A new IMF assistance program, expected to start in 2015, will guide the government’s economic policies and help reduce the fiscal deficit by cutting subsidies, reducing the bloated public sector wage bill, and strengthening revenue administration, but related austerity measures will be unwelcomed by the public.

Source : CIA

 


 

SUBJECT'S NAME

 

 

Registered Name:

POKUPHARMA GHANA LTD

Requested Name:

POKUPHARMA GHANA LTD

Other Names:

None

 

 

 

ADDRESS AND TELECOMMUNICATION

 

Physical Address:

Near Asafo Ahmadiyya Mosque

Postal Address:

P. o. Box 3009/64220

 

Kumasi,

Country:

Ghana

Phone:

233-322064222/4/5/33135/81597

Fax:

233-322064221/81596

Email:

kwame@pokupharmagh.com/ kwaku@pokupharmagh.com/

amina@pokupharmagh.com

Website:

www.pokupharmagh.com

 

 

 

CREDIT OPINION

 

 

Financial Index as of December 2014 shows subject firm with a medium risk of credit. However, bank and credit information obtained reveal a history of prompt payments.

 

 

LEGAL

 

 

 

Legal Form:

Limited Corporation 

Date Incorporated:

05-March-1998

Reg. Number:

CA 32859

Nominal Capital

GHS. 100,000

Subscribed Capital

GHS. 100,000

Subscribed Capital is Subscribed in the following form:

 

Position

Shares

Dr. Kwame Opoku

CEO

 

Mr. Kwaku Opoku – Adjei

Director

 

Mrs. Amina Ahmed

Director

 

Mr. Stephen Danso-Mensah

GM

 

Mr. Abass Rabbi

Accounts

 

 

 

RELATED COMPANIES

 

None

Parent company.

None

Subsidiary company.

MARINA CHEMIST LIMITED

Affiliated company.

None

Shareholder of subject firm.

None

Branches of the firm

 

 

 

OPERATIONS

 

Registered to operate as suppliers of pharmaceutical products and medicinal drugs

Imports:

Asia, South Africa

Exports:

None

Trademarks:

None

Terms of sale:

Cash (70%) and 25-90 days (30%), invoices.

 

 

Main Customers:

Local agencies, medical stores, firms and organizations  

Employees:

25 employees.

Vehicles:

Several motor vehicles.

Territory of sales:

Ghana

Location:

Leased premises, 10,000 square feet,

 

 

 

AUDITORS AND INSURANCE

 

 

Auditors:

Information not available.

Insurance Brokers:

Information not available.

 

 

 

FINANCE

 

 

 

Currency Reported:

Ghanaian Cedi (GHS.)

Approx. Ex. Rate:

1 US Dollar = 3.87 Ghanaian Cedi

Fiscal Year End:

December 31, 2014

Inflation:

According to information given by independent sources, the inflation at December 31st, 2014 was of 13%.

 

Financial Information not Submitted

 

 

 

 

 

Profit and Loss (expressed in GHS.)

 

2013

2014

Sales

15,300,000

26,200,000

 

 

BANK

 

 

 

Bank Name:

Zenith Bank

Branch:

Ghana

Comments:

None

 

 

 

TRADE REFERENCES

 

 

Experiences:

Good

 

 

_______________________________________________________________________

NOTARIAL BONDS

None

 

 

 

COMMENTS / ADDITIONAL INFORMATION

 

 

This information was obtained from outside sources other than the subject company itself and confirmed the above subject.

 

 

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs. 63.51

UK Pound

1

Rs. 95.95

Euro

1

Rs. 70.53

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

DPT

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.